1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Encephalitis – Pipeline Review, H1 2013

Encephalitis – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 102 pages

Encephalitis – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Encephalitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalitis. Encephalitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Encephalitis.
- A review of the Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Encephalitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Encephalitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Encephalitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Encephalitis - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Encephalitis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Encephalitis 8
Encephalitis Therapeutics under Development by Companies 10
Encephalitis Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Encephalitis Therapeutics - Products under Development by Companies 18
Encephalitis Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Encephalitis Therapeutics Development 21
Sanofi-Aventis 21
CEL-SCI Corporation 22
Intercell AG 23
CytoGenix, Inc. 24
Array BioPharma Inc. 25
Panacea Biotec Limited 26
Functional Genetics, Inc. 27
Palau Pharma S.A 28
AlphaVax, Inc. 29
Sinovac Biotech Ltd. 30
Wittycell S.A.S. 31
Vaxart, Inc. 32
Hawaii Biotech, Inc. 33
NasVax Ltd. 34
China National Pharmaceutical Group Corporation 35
Inviragen, Inc. 36
Prosetta Corporation 37
Vaxine Pty Ltd 38
Encephalitis - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
DNA Vaccine For Viral Infection - Drug Profile 45
CEL-1000 - Drug Profile 47
Equine Encephalitis Vaccine - Drug Profile 50
CST-102 - Drug Profile 51
tacrolimus - Drug Profile 52
Ixiaro - Drug Profile 53
VRC-WNVDNA020-00-VP - Drug Profile 55
Western Equine Encephalitis Vaccine - Drug Profile 56
japanese encephalitis vaccine (live attenuated) - Drug Profile 57
VEE TC-83 - Drug Profile 59
VEE C-84 - Drug Profile 60
CIGB-845 - Drug Profile 61
Japanese Encephalitis Chimeric Virus Vaccine + MMR Vaccine - Drug Profile 62
Anti-aCD3 Mab - Drug Profile 64
TSI-GSD-104 - Drug Profile 66
Inactivated Vero Cell Derived Japanese Encephalitis Vaccine - Drug Profile 67
JE/WNV - Drug Profile 68
Jak3/Syk Dual Inhibitor - Drug Profile 69
Japanese Encephalitis Vaccine - Drug Profile 70
PolyMap - Drug Profile 71
AR-460770 - Drug Profile 72
Drugs For Viral Encephalitis - Drug Profile 73
FGI-104 - Drug Profile 74
WTCa Adjuvant - Drug Profile 75
WTCb Adjuvant - Drug Profile 77
WTCn Adjuvant - Drug Profile 79
Tick-Borne Flavivirus Vaccine - Drug Profile 81
JE Vaccine - Drug Profile 82
Vaccine Against Venezuelan Equine Encephalitis - Drug Profile 83
Antiviral Agents - Drug Profile 84
Japanese Encephalitis Vaccine - Drug Profile 85
Venezuelan Equine Encephalitis Vaccine - Drug Profile 86
Encephalitis Therapeutics - Drug Profile Updates 87
Encephalitis Therapeutics - Discontinued Products 89
Encephalitis Therapeutics - Dormant Products 90
Encephalitis - Product Development Milestones 92
Featured News and Press Releases 92
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100



List of Tables

Number of Products Under Development for Encephalitis, H1 2013 10
Products under Development for Encephalitis - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Sanofi-Aventis, H1 2013 23
CEL-SCI Corporation, H1 2013 24
Intercell AG, H1 2013 25
CytoGenix, Inc., H1 2013 26
Array BioPharma Inc., H1 2013 27
Panacea Biotec Limited, H1 2013 28
Functional Genetics, Inc., H1 2013 29
Palau Pharma S.A, H1 2013 30
AlphaVax, Inc., H1 2013 31
Sinovac Biotech Ltd., H1 2013 32
Wittycell S.A.S., H1 2013 33
Vaxart, Inc., H1 2013 34
Hawaii Biotech, Inc., H1 2013 35
NasVax Ltd., H1 2013 36
China National Pharmaceutical Group Corporation, H1 2013 37
Inviragen, Inc., H1 2013 38
Prosetta Corporation, H1 2013 39
Vaxine Pty Ltd, H1 2013 40
Assessment by Monotherapy Products, H1 2013 41
Assessment by Combination Products, H1 2013 42
Assessment by Stage and Route of Administration, H1 2013 44
Assessment by Stage and Molecule Type, H1 2013 46
Encephalitis Therapeutics - Drug Profile Updates 89
Encephalitis Therapeutics - Discontinued Products 91
Encephalitis Therapeutics - Dormant Products 92
Encephalitis Therapeutics - Dormant Products (Contd..1) 93



List of Figures

Number of Products under Development for Encephalitis, H1 2013 10
Products under Development for Encephalitis - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 41
Assessment by Combination Products, H1 2013 42
Assessment by Route of Administration, H1 2013 43
Assessment by Stage and Route of Administration, H1 2013 44
Assessment by Molecule Type, H1 2013 45
Assessment by Stage and Molecule Type, H1 2013 46

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.